Update on stress ulcer prophylaxis in critically ill patients

Critical Care Nurse

Volumn 26, Issue 1, 2006, Pages 18-28

  Spirt, Mitchell J ^a,b   Stanley, Sandra ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Centry City Doctors Hospital   (United States)

^c Specialty Surgical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIULCER AGENT; HISTAMINE AGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE;

ARTIFICIAL VENTILATION; CRITICAL ILLNESS; DRUG ANTAGONISM; DRUG MONITORING; HUMAN; INTENSIVE CARE; ISCHEMIA; METHODOLOGY; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; PEPTIC ULCER; PEPTIC ULCER BLEEDING; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; STOMACH MUCOSA; STRESS; VASCULARIZATION;

ANTACIDS; ANTI-ULCER AGENTS; CRITICAL CARE; CRITICAL ILLNESS; DRUG MONITORING; GASTRIC MUCOSA; H(+)-K(+)-EXCHANGING ATPASE; HISTAMINE AGONISTS; HUMANS; ISCHEMIA; NURSE'S ROLE; NURSING ASSESSMENT; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RISK FACTORS; STRESS;

EID: 33645048752     PISSN: 02795442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Lev R, Molot MD, McNamara J, Stremple JF. "Stress" ulcers following war wounds in Vietnam: a morphologic and histochemical study. Lab Invest. 1971;25:491-502.
2. ASHP Commission on Therapeutics. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56:347-379.
3. Czaja AJ, McAlhany JC, Pruitt BA Jr. Acute gastroduodenal disease after thermal injury: an endoscopic evaluation of incidence and natural history. N Engl J Med. 1974;291:925-929.
4. Peura DA, Johnson LF. Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med. 1985;103:173-177.
5. Munakata A, Aisawa T, Yoshida Y, Tanaka S. Prospective study of acute gastric mucosal lesion (AGML) in patients receiving open heart surgery under extra-corporeal circulation [abstract]. Gastrointest Endosc. 1987;33:151. Abstract 35.
6. Spirt MJ. Acute Care of the Abdomen. Baltimore, Md: Williams & Wilkins; 1998.
7. Cook DJ, Reeve BK, Guyatt GH, et al. Stress Weer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA. 1996;275:308-314.
8. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330:377-381.
9. Ben-Menachem T, Fogel R, Patel RV, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit: a randomized, controlled, single-blind study. Ann Intern Med. 1994;121:568-575.
10. Schuster DP, Rowley H, Feinstein S, McGue MK, Zuckerman GR. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med. 1984;76:623-630.
11. Spirt MJ. Acid suppression in critically ill patients: what does the evidence support? Pharmacotherapy. 2003;23(suppl):87S-93S.
12. Lucas CE, Sugawa C, Riddle J, et al. Natural history and surgical dilemma of "stress" gastric bleeding. Arch Surg. 1971;102:266-273.
13. Zuckerman GR, Shuman R. Therapeutic goals and treatment options for prevention of stress ulcer syndrome. Am J Med. 1987; 83:29-35.
14. Spirt MJ. Stress-related mucosal disease. Curr Treat Options Gastroenterol. 2003;6: 135-145.
15. Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002; 30(suppl):S351-S355.
16. Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother. 2002;36: 1929-1937.
17. Beejay U, Wolfe MM. Acute gastrointestinal bleeding in the intensive care unit: the gastroenterologist's perspective. Gastroenterol Clin North Am. 2000;29:309-336.
18. Dive A, Moulart M, Jonard P, Jamart J, Mahieu P. Gastroduodenal motility in mechanically ventilated critically ill patients: a manometric study. Crit Care Med. 1994; 22:441-447.
19. Spirt MJ, Guth PH, Randall G, Leung FW. Gastroduodenal perfusion and mortality in mechanical ventilation-dependent patients with systemic inflammatory response syndrome. Dig Dis Sci. 2004;49:906-913.
20. Anlatici R, Ozerdem OR, Dalay C, et al. A retrospective analysis of 1083 Turkish patients with serious bums, II: burn care, survival and mortality. Burns. 2002;28:239-243.
21. Pimentel M, Roberts DE, Bernstein CN, Hoppensack M, Duerksen DR. Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. Am J Gastroenterol. 2000;95:2801-2806.
22. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-883.
23. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs. 1997;54: 581-596.
24. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA. 1994;272: 1354-1357.
25. MacLaren R, Jarvis CL, Fish DN. Use of enteral nutrition for stress ulcer prophylaxis. Ann Pharmacother. 2001;35:1614-1623.
26. Raff T, Germann G, Hartmann B. The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient. Burns. 1997;23:313-318.
27. Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med. 1999;27: 2812-2817.
28. Barletta JF, Erstad BL, Fortune JB. Stress ulcer prophylaxis in trauma patients. Crit Care. 2002;6:526-530.
29. Erstad BL, Barletta JF, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. Crit Care. 1999;3:145-149.
30. Lam NP, Le PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Crit Care Med. 1999;27:98-103.
31. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997;42:1255-1259.
32. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology. 1994;106:60-64.
33. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338:791-797.
34. Darlong V, Jayalakhsmi TS, Kaul HL, Tandon R. Stress ulcer prophylaxis in patients on ventilator. Trop Gastroenterol. 2003;24: 124-128.
35. Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 2004;51:757-761.
36. Hemstreet BA. Use of sucralfate in renal failure. Ann Pharmacother. 2001;35:360-364.
37. Martin LF, Booth FV, Karlstadt RG, et al. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med. 1993;21:19-30.
38. Zinner MJ, Zuidema GD, Smith P, Mignosa M. The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit. Surg Gynecol Obstet. 1981; 153:214-220.
39. Weigelt JA, Aurbakken CM, Gewertz BL, Snyder WH III. Cimetidine vs antacid in prophylaxis for stress ulceration. Arch Surg. 1981;116:597-601.
40. Kingsley AN. Prophylaxis for acute stress ulcers: antacids or cimetidine. Am Surg. 1985;51:545-547.
41. Azevedo JR, Soares MG, Silva G, Palacio G. Prevention of stress ulcer bleeding in high risk patients: comparison of three drugs [abstract]. Crit Care Med. 1999;27:A41.
42. Hastings PR, Skillman JJ, Bushnell LS, Silen W. Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients. N Engl J Med. 1978;298:1041-1045.
43. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma. 1998;44:527-533.
44. Phillips JO, Metzler MH, Palmieri TL, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med. 1996;24:1793-1800.
45. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol. 1999;94:351-357.
46. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40:523-537.
47. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999;13(suppl 3):18-26.
48. Meyer UA. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996;69:203-209.
49. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985;89:1235-1241.
50. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glyco-protein. Naunyn Schmiedebergs Arch Pharmacol. 2001;364:551-557.
51. Kokufu T, Ihara N, Sugioka N, et al. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol. 1995;48:391-395.
52. Dixit RK, Chawla AB, Kumar N, Garg SK. Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers. Methods Find Exp Clin Pharmacol. 2001;23:37-39.
53. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32:569-572.
54. Welage LS, Berardi RR. Drug Interactions with antiulcer agents: considerations in the treatment of acid-peptic disease. J Pharm Pract. 1994;6:177-195.
55. Wolfe MM, Welage LS, Sachs G. Proton pump inhibitors and gastric acid secretion. Am J Gastroenterol. 2001;96:29-30.
56. Santarus Inc. Zegerid [package insert]. Whitby, Ontario: Patheon Inc; 2004.
57. Aris R, Karlstadt R, Paoletti V, Blatcher D, McDevitt J. Intermittent intravenous pantoprazole achieves a similar onset time to pH ≥4.0 in ICU patients as continuous infusion H2-receptor antagonist, without tolerance. Paper presented at: 66th Annual Scientific Meeting of the American College of Gastroenterology; October 2001; Las Vegas, Nev.
58. Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2000;95:626-633.
59. Wyeth Pharmaceuticals. Protonix IV. [package insert]. Philadelphia, Pa: Wyeth Laboratories; 2004.
60. TAP Pharmaceuticals Inc. Prevacid IV [package insert]. Lake Forest, Ill: TAP Pharmaceuticals Inc; 2004.
61. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004; 32:2008-2013.
62. Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med. 2002;30(6 suppl):S373-S378.
63. Devlin JW, Claire KS, Dulchavsky SA, Tyburski JG. Impact of trauma stress ulcer prophylaxis guidelines on drug cost and frequency of major gastrointestinal bleeding. Pharmacotherapy. 1999;19:452-460.
64. Pitimana-aree S, Forrest D, Brown G, Anis A, Wang XH, Dodek P. Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care. Intensive Care Med. 1998;24:217-223.
65. Mostafa G, Sing RF, Matthews BD, Pratt BL, Norton HJ, Heniford BT. The economic benefit of practice guidelines for stress ulcer prophylaxis. Am Surg. 2002;68:146-150.
66. Schupp KN, Schrand LM, Mutnick AH. A cost-effectiveness analysis of stress ulcer prophylaxis. Ann Pharmacother. 2003;37:631-635.
67. Flannery J, Tucker DA. Pharmacologic prophylaxis and treatment of stress ulcers in critically ill patients. Crit Care Nurs Clin North Am. 2002;14:39-51.
68. Allen ME, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm. 2004;61:588-596.
69. Bradley JS, Phillips JO, Cavanaugh JE, Metzler MH. Clinical utility of pH paper versus pH meter in the measurement of critical gastric pH in stress ulcer prophylaxis. Crit Care Med. 1998;26:1905-1909.
70. Holland EG, Taylor AT. Practical management of stress-related gastric ulcers. J Fam Pract. 1991;33:625-632.